Evidence map›Paper›PMID 31566564›Full record

ArticleeLife2019

Molecular mechanism of TRPV2 channel modulation by cannabidiol.

Ruth A Pumroy, Amrita Samanta, Yuhang Liu, Taylor Et Hughes, Siyuan Zhao, Yevgen Yudin, Tibor Rohacs, Seungil Han, Vera Y Moiseenkova-Bell

Open access · goldAbstract read
In one paragraph

Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. An Extracellular Pore‑Targeting Peptide Defines a Designable Allosteric Site in TRPV2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Structural insights into TRPV2 modulation by probenecid.Nature structural & molecular biology · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Cannabinoid inhibition of mechanosensitive KbioRxiv : the preprint server for biology · 2024
    Article
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ruth A PumroyDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.ORCID 0000-0002-6200-6083
Amrita SamantaDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
Yuhang LiuPfizer Research and Development, Groton, United States.ORCID 0000-0001-6844-7480
Taylor Et HughesDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
Siyuan ZhaoDepartment of Pharmacology, Physiology and Neuroscience, New Jersey Medical School, Rutgers University, Newark, United States.
Yevgen YudinDepartment of Pharmacology, Physiology and Neuroscience, New Jersey Medical School, Rutgers University, Newark, United States.
Tibor RohacsDepartment of Pharmacology, Physiology and Neuroscience, New Jersey Medical School, Rutgers University, Newark, United States.ORCID 0000-0003-3580-2575
Seungil HanPfizer Research and Development, Groton, United States.ORCID 0000-0002-1070-3880
Vera Y Moiseenkova-BellDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.ORCID 0000-0002-0589-4053
Translational Therapeutics (United States) · USRutgers, The State University of New Jersey · USPfizer (United States) · US

Funding

Regulation of sensory TRP channels by phospholipids and G-proteinsR01NS055159 · NINDS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI ROHACS, TIBOR · 2007 to 2022
$5.9M
Regulation of the Intestinal Ca2+ Channels TRPV6R01GM093290 · NIGMS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI CARNEVALE, VINCENZO, ROHACS, TIBOR · 2011 to 2025
$4.9M
Structural Insights into TRPV Channel GatingR01GM103899 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI MOISEENKOVA-BELL, VERA · 2013 to 2021
$3.2M
Molecular mechanisms of TRPV5 gatingR01GM129357 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI MOISEENKOVA-BELL, VERA · 2018 to 2021
$1.7M
Molecular mechanism of TRPV1 activationR01GM131048 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI CARNEVALE, VINCENZO, ROHACS, TIBOR · 2019 to 2022
$1.4M
NIGMS NIH HHS R01 GM093290NIGMS NIH HHS R01 GM103899NIGMS NIH HHS R01 GM129357NIGMS NIH HHS R01 GM131048NIH HHS R01GM093290NIH HHS R01GM103899NIH HHS R01GM129357NIH HHS R01 NS055159NINDS NIH HHS R01 NS055159
6 · The paper itself

Abstract

Transient receptor potential vanilloid 2 (TRPV2) plays a critical role in neuronal development, cardiac function, immunity, and cancer. Cannabidiol (CBD), the non-psychotropic therapeutically active ingredient of

Indexed as

AnimalsBinding SitesCannabidiolCannabisCryoelectron MicroscopyHumansHydrophobic and Hydrophilic InteractionsLigandsLipidsMutationProtein Conformation, alpha-HelicalProtein Structure, SecondaryRatsTRPV Cation ChannelsCannabidiolLigandsLipidsTrpv2 protein, ratTRPV Cation Channelscannabidiolcryo-EMion channelsmolecular biophysicsS. cerevisiaestructural biologyTRP channels

Identifiers

PMID31566564
PMCPMC6794088
OpenAlexW2978944334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.